GSK’s Promacta And Amgen’s Nplate Face Off In ITP Market
Executive Summary
GlaxoSmithKline/Ligand's Promacta (eltrombopag) received FDA approval Nov. 20 as a second-line treatment of thrombocytopenia in patients with the rare blood disorder chronic idiopathic thrombocytopenic purpura. The approval was widely anticipated, although it came five months after the drug's original PDUFA date
You may also be interested in...
NICE Rejects Revolade For Bleeding Disorders; GSK Considering Its Options
UK's cost effectiveness watchdog is uncertain about Revolade's long-term effects and cost
NICE Rejects Revolade For Bleeding Disorders; GSK Considering Its Options
UK's cost effectiveness watchdog is uncertain about Revolade's long-term effects and cost
Amgen’s Nplate Has First Mandatory Patient Registration Under REMS
The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients